Drugs In The News

Shalyn Quigley, PharmD; PGY1 General Practice Resident, Millcreek Community Hospital in Erie, PA When hemostatic balance is interrupted by stasis, stress, or hypercoagulabilty, patients are at risk for venous or arterial thrombosis that may require medical prophylaxis or treatment. In the low shear venous system, thrombi are composed of red blood cells trapped by fibrin

Camille Zambrana, PharmD Candidate; Marcus Campbell, PharmD, BC-ADM Patients with COPD experience exacerbations approximately 1 to 2 times per year; those with frequent episodes are reported to have a more rapid decline in overall lung function.  Exacerbations are triggered by a number of factors (i.e., exposure to pollutants and interruption of maintenance therapy), but the

Wycliffe Mugoya, PharmD Candidate; Marcus Campbell, PharmD, BC-ADM, Ryan Wargo, PharmD, BCACP Recently, FDA approved GlaxoSmithKline’s Breo Ellipta; an inhaled corticosteroid and long-acting beta agonist (ICS/LABA) combination product for long-term maintenance therapy in COPD patients. Breo Ellipta contains 100 mcg of fluticasone furoate and 25 mcg of vilanterol, which is administered via dry powder inhaler once

A Novel COPD Medication

Saturday, 02 November 2013

Keith Sawh, PharmD Candidate; Marcus Campbell, PharmD, BC-ADM Presently, no pharmacological treatment is shown to modify the rate of decline in lung function or disease progression.  Patients are commonly treated with bronchodilators to improve symptoms and reduce exacerbations: long-acting muscarinic antagonists (LAMAs) and long-acting β2-agonists (LABAs). LAMAs and LABAs can be used as monotherapy or in combination

November is COPD awareness month

Friday, 01 November 2013

Keith Sawh, PharmD Candidate; Marcus Campbell, PharmD, BC-ADM Chronic Obstructive Pulmonary Disease (COPD) is an airway disease characterized by long term progressive airflow limitation. The most common symptoms exhibited by COPD patients include dyspnea, chronic cough with sputum production, tiredness, chest tightness, and limitations of activity. The National Heart, Lung, and Blood Institute (NHLBI) estimates

Kevin Olivieri, PharmD Candidate; Michael Mueller, PhD Until recently, no FDA approved treatment was available for systemic juvenile idiopathic arthritis (sJIA), a disease from which an estimated 250,000 children suffer in the US alone.1  On May 10, 2013 the biologic interleukin-1 beta antagonist Ilaris®, (canakinumab) was approved for the treatment of sJIA in children aged 2

Eric Yeo, PharmD Candidate; Marcus Campbell, PharmD, BC-ADM Osteoporosis is a disease associated with a reduction in bone mass and an increase in skeletal fragility. It affects 10 million Americans; another 34 million are considered at risk.1 Bisphosphonates have been shown to be effective in reducing the risk of osteoporotic fragility fractures, and are widely prescribed for

Lucas Reinhartz, PharmD Candidate; Michael Mueller, PhD Gonorrhea remains the second most commonly reported sexually transmitted disease in the United States behind chlamydia.1 Prevention and treatment of N. gonorrheae, through safe sex practices and antibiotics, can result in a decrease of male patients with epididymitis and female patients with pelvic inflammatory disease and the possibility of

Kathryn Samai, PharmD, BCPS Elderly patients have several unique issues related to antibiotic therapy. In addition to age-associated physiological changes and drug-drug interactions, adverse drug reactions are also a noteworthy concern specific to this population. By using evidence-based medicine, pharmacists can help identify, prevent and resolve adverse drug related problems in the elderly. Common adverse

Michael Golding, PharmD Candidate; Katherine Tromp, PharmD Pertussis, an illness characterized by a whooping cough, is caused by the bacteria Bordetella Pertussis. The disease frequently affects young children and infants. In the prevaccine era, pertussis was very common and a major cause of childhood mortality in the United States. Since the institution of routine childhood